Cogent Biosciences
COGT
135 hedge funds and large institutions have $859M invested in Cogent Biosciences in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 21 closing their positions.
4,929% more call options, than puts
Call options by funds: $704K | Put options by funds: $14K
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% more funds holding
Funds holding: 134 → 135 (+1)
8.57% less ownership
Funds ownership: 115.69% → 107.12% (-8.6%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
24% less capital invested
Capital invested by funds: $1.13B → $859M (-$270M)
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$18.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$13.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.47M |
Top Sellers
COGT Hedge Fund Activity: Q4 2022 in Review
135 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2022, worth a combined $859M — down 24% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new COGT positions and 21 closed out — a net gain of 1 holder — while 53 added to existing stakes and 37 trimmed.
The largest buyer was RA Capital Management, adding an estimated $24.6M. The largest seller was Janus Henderson Group, cutting an estimated $22M.
- 135 institutional investors held Cogent Biosciences (COGT) as of Q4 2022, up from 134 in Q3 2022.
- Funds reported $859M of Cogent Biosciences stock for Q4 2022, down 24% quarter-over-quarter.
- 22 funds opened new Cogent Biosciences positions in Q4 2022 and 21 closed out, a net change of +1 holder.
- The largest Cogent Biosciences buyer in Q4 2022 was RA Capital Management, an estimated $24.6M added.
- The largest Cogent Biosciences seller in Q4 2022 was Janus Henderson Group, an estimated $22M sold.
Based on aggregated 13F filings for Q4 2022.